We are all expecting good impressive data today, in general.

But the other thing that I will be looking for, and looking forward to discussions on, are limiting data/factors as well ... where are the “bogeys” to moving forward? So, if we have really good data that looks promising for moving forward either soon or in the future, what are the limiting factors and major questions and issues that the FDA could dwell upon and have a need to better understand and resolve, that may require more data?

I doubt that we get a ton of clarity on those specific things from Don on Monday, but again it is back to body language and enthusiasm from Don on Monday about the prospects for moving forward and how? Certainly he won’t reveal those specific things pending the FDA letter, but he has been known to drop a few clues ha ha